BrainsWay Ltd. (BWAY) Stock Price & Analysis
BrainsWay Ltd. (BWAY) closed at USD 11.37 on Wednesday, October 28, 2026, down 2.24% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 11.63; the Oct 28, 2026 session ranged USD 11.02–11.63 on volume of 89,435 shares. Market capitalization is $457.68M, with a 52-week range of USD 7.14–17.4 (NGM). Source: Nexqual, retrieved October 29, 2026 at 08:51 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BWAY.md
Key facts (BWAY)
- Insider open-market sales, last ~7 months: 3 Form 4 filings, $0K; 3 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (3 analysts), mean target USD 19.27 (range 18.8–20).
- Total return with dividends: 1Y +35.3% vs S&P 500 +13.6%; 5Y +178.0% vs S&P 500 +79.8%.
- Next earnings: 2026-11-10, EPS estimate USD 0.09, revenue estimate $17.8M.
Insider sales (SEC Form 4, open-market, last ~7 months) (BWAY)
0 of 3 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-15 | Moiseyev Gilad | Chief Technology Officer | 5,000 | $0K | 8.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-06-01…2026-06-02 | Roth Yiftach | Chief Scientist | 7,000 | $0K | 0.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-25…2026-05-26 | Mitrany Rayten Michal Ety | Director | 17,980 | $0K | 59% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (BWAY)
Consensus Buy (mean 2.00 on a 1–5 scale), 3 analysts; mean target USD 19.27 (low 18.8, high 20).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | HC Wainwright & Co. | Reiterated | Buy | $19 |
| 2026-09-10 | BTIG | Reiterated | Buy | $20 |
| 2026-09-08 | HC Wainwright & Co. | Reiterated | Buy | $19 |
| 2026-08-31 | HC Wainwright & Co. | Target raised | Buy | $17 → $19 |
| 2026-08-13 | Ladenburg Thalmann | Target raised | Buy | $18 → $18.8 |
| 2026-08-12 | BTIG | Target raised | Buy | $18 → $20 |
| 2026-07-20 | BTIG | Initiated | Buy | $18 |
| 2026-07-02 | HC Wainwright & Co. | Reiterated | Buy | $17 |
Total return (dividends reinvested) (BWAY)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +35.3% | +178.0% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +35.5% | +22.6% |
| Volatility (annualized) | 53.0% | 64.1% |
| Max drawdown | -34.7% (May 2026→Oct 2026) | -83.4% (Apr 2022→May 2023) |
BWAY earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $0.07 | $0.07 | In line | — |
| — | Quarter ended Mar 31, 2026 | $0.06 | $0.05 | Beat +20.0% | — |
| — | Quarter ended Dec 31, 2025 | $0.06 | $0.03 | Beat +$0.03 | — |
| — | Quarter ended Sep 30, 2025 | $0.02 | $0.02 | In line | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
BWAY recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 26, 2026 | 6-K/A | Current report (foreign issuer) · period ended Oct 26, 2026 |
| Oct 26, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 26, 2026 |
| Oct 21, 2026 | 6-K | Current report (foreign issuer) · period ended Nov 25, 2026 |
| Oct 19, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 19, 2026 |
| Oct 13, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 13, 2026 |
| Sep 29, 2026 | 6-K | Current report (foreign issuer) · period ended Jun 30, 2026 |
| Sep 8, 2026 | 6-K | Current report (foreign issuer) · period ended Sep 8, 2026 |
| Aug 27, 2026 | 6-K | Current report (foreign issuer) · period ended Aug 27, 2026 |
| Aug 12, 2026 | 6-K | Current report (foreign issuer) · period ended Aug 12, 2026 |
| Aug 12, 2026 | 6-K | Current report (foreign issuer) · period ended Aug 12, 2026 |
| Jul 29, 2026 | Schedule 13G/A | Harel Insurance Investments & Financial Services Ltd.: 8.3% of shares, passive 5%+ holder (amended) |
| Jul 20, 2026 | 6-K | Current report (foreign issuer) · period ended Jul 20, 2026 |
| Jul 16, 2026 | 6-K | Current report (foreign issuer) · period ended Jul 16, 2026 |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
BWAY suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Yeda Research and Development Company | “is also licensed to us under the PHS license agreement and our license agreement with Yeda.” |
Quoted from the company's 20-F filed Apr 20, 2026.
BWAY analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.09 | $0.09 | +0.0% | $17.8M | 3 |
| Next quarter (ends Dec 2026) | $0.09 | $0.09 | +3.7% | $18.7M | 3 |
| Current fiscal year (ends Dec 2026) | $0.31 | $0.31 | +0.0% | $69.2M | 3 |
| Next fiscal year (ends Dec 2027) | $0.51 | $0.48 | +4.8% | $85.3M | 3 |
BWAY options: expected move
Options price a move of about ±65.1% (±$7.41) by Jan 15, 2027, which includes earnings on Nov 10, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Jan 15, 2027 | 78 | 113.9% | ±65.1% |
| Apr 16, 2027 | 169 | 85.5% | ±47.9% |
30-day implied volatility 103.2% vs 38.5% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 08:51 UTC)
| Price | USD 11.37 |
|---|---|
| Change | ▼ 2.24% (down) |
| Previous Close | USD 11.63 |
| Open | USD 11.63 |
| Day Range | USD 11.02 – 11.63 |
| 52-Week Range | USD 7.14 – 17.4 |
| Volume | 89,435 shares |
| Market Cap | $457.68M |
| Exchange | NGM |
Technical Analysis (BWAY)
Nexqual's technical model rates BWAY "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 08:51 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 37.84 (neutral) |
| vs SMA50 | Below (USD 13.09) |
| MACD | -0.49 (negative) |
Analyst Ratings (BWAY)
Wall Street analysts rate BWAY "Buy" based on 3 analysts, with a mean price target of USD 19.27 (range USD 18.8–20), per Nexqual as of October 29, 2026 at 08:51 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 19.27 |
| High Target | USD 20 |
| Low Target | USD 18.8 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (BWAY)
| Next Earnings Date | 2026-11-10 |
|---|---|
| EPS Estimate | USD 0.09 |
| Revenue Estimate | $17.80M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.07 vs est 0.07 ▼ miss |
| 2026-03-31 | USD 0.06 vs est 0.05 ▲ beat |
| 2025-12-31 | USD 0.06 vs est 0.03 ▲ beat |
| 2025-09-30 | USD 0.02 vs est 0.02 ▼ miss |
Source: Nexqual, October 29, 2026 at 08:51 UTC.
Financials & Fundamentals (BWAY)
| Total Revenue | $60.70M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +35.40% |
| Gross Margin | +75.32% |
| Operating Margin | +13.98% |
| Profit Margin | +15.55% |
| ROE | +12.82% |
| Debt / Equity | 0.09 |
| Current Ratio | 3.59 |
| Total Cash | $62.11M |
| Total Debt | $7.13M |
Source: Nexqual, October 29, 2026 at 08:51 UTC.
Financial Health Score (BWAY)
Nexqual rates BrainsWay Ltd.'s overall financial health "Solid" across five dimensions, as of October 29, 2026 at 08:51 UTC.
| Growth | Strong — Revenue +27% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 75%, operating 14% (last 12 months) |
| Balance Sheet | Strong — $62M cash vs $7M debt, net cash position |
| Cash Flow | Solid — Operating cash flow $8M (TTM) |
| Efficiency | Mixed — ROE 13%, ROA 4.0% |
Ownership (BWAY)
| Insider Ownership | +6.09% |
|---|---|
| Institutional Ownership | +29.43% |
| Shares Outstanding | 40.25M |
| Float | 24.11M |
| Short % of Float | +0.74% |
Source: Nexqual, October 29, 2026 at 08:51 UTC.
Leadership (BWAY)
BrainsWay Ltd. is led by Hadar Levy, Chief Executive Officer, per Nexqual as of October 29, 2026 at 08:51 UTC.
| Chief Executive Officer | Hadar Levy |
|---|---|
| Co-Founder & Vice-Chairman | David Zacut |
| Co-Founder, Member of Scientific Advisory Board & Director | Abraham Zangen |
| Chief Financial Officer | Ido Marom |
| Vice President of Medical Affairs | Colleen Hanlon |
Major Backers & Investors (BWAY)
Notable institutional backers of BrainsWay Ltd. include Valor Management LLC, Masters Capital Management, LLC, Acadian Asset Management. LLC, according to Nexqual as of October 29, 2026 at 08:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Valor Management LLC | 13.2% |
| Masters Capital Management, LLC | 3.73% |
| Acadian Asset Management. LLC | 2.01% |
| Essex Investment Management Co LLC | 1.43% |
| Renaissance Technologies | 1.18% |
| Cresset Asset Management, LLC | 0.78% |
| Hwg Holdings Lp | 0.63% |
| Y.D. More Investments Ltd | 0.59% |
Source: Nexqual, October 29, 2026 at 08:51 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BFLY | Butterfly Network, Inc. | USD 7.81 | ▲ 5.83% |
| ESTA | Establishment Labs Holdings Inc | USD 68.97 | ▲ 3.02% |
| INSP | Inspire Medical Systems, Inc. | USD 70.97 | ▼ 0.46% |
| UFPT | UFP Technologies, Inc. | USD 286 | ▼ 3% |
| ALMR | Alamar Biosciences, Inc. | USD 34.3 | ▲ 7.42% |
| TMDX | TransMedics Group, Inc. | USD 66.9 | ▼ 4.06% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 08:51 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt